Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
Lorenz Räber, Vice President of Swiss Society of Cardiology, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Nature Reviews Cardiology, adding:
“Intracoronary imaging in PCI: Why, when, how—and which modality? Insights from large randomized controlled trials
Our review has just been published in Nature reviews cardiology, part of Springer Nature
The publication of eight large international randomized controlled trials (each including more than 1,000 patients)—ILUMIEN IV, IVUS-ACS, IVUS-CHIP, IVUS-XPL, OCCUPI, OCTOBER, RENOVATE-COMPLEX, and ULTIMATE—has generated substantial evidence supporting the clinical use of intracoronary imaging (ICI) to improve outcomes in patients undergoing PCI.
However, heterogeneity in study populations, the lack of standardized criteria across ICI-guided PCI protocols, and mixed results across randomized trials have left important uncertainty regarding why, when, and in whom ICI guidance provides the greatest clinical benefit in daily practice.
In this 20-page review, we discuss all major randomized controlled trials of intracoronary imaging guidance—including the latest IVUS-CHIP and OPTIMAL—and provide a practical perspective on the optimal use of IVUS and OCT in contemporary PCI.
A big thanks to Flavio Biccirè (former Bern fellow, now Interventional Consultant at San Giovanni Addolorata, Rome) for his great endurance and commitment throughout this endeavour, and to all our co-author colleagues from Spain, Korea and USA who contributed to this work.
- Professor Ik-Kyung Jang from Boston Massachusetts General Hospital, Boston, USA
- Nieves Gonzalo from Hospital Clinico San Carlos, Computense de Madrid University, Madrid, Spain
- Professor Joo-Yong Hahn from Samsung Medical Center, Sungkyunkwan University, Seol, Korea
Thanks to Dr Gregory Lim for his editorial guidance.”
Title: Intracoronary imaging in percutaneous coronary intervention: why, when, how and which from large, randomized trials
Authors: Flavio Giuseppe Biccirè, Nieves Gonzalo, Joo-Yong Hahn, Ik-Kyung Jang, Lorenz Räber

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics